Annovis Bio Secures $10 Million Financing to Advance Neurodegenerative Disease Treatment Through 2027

Annovis Bio Inc., a clinical-stage biotechnology company, has closed an underwritten public offering raising approximately $10 million in gross proceeds. This financing, combined with existing cash and a recent $1.5 million investment from Board Chair Michael Hoffman, is expected to extend the company's cash runway through the second quarter of 2027. The funds are crucial for supporting operations through a key six-month symptomatic data readout from its Phase 3 Alzheimer's disease trial and the anticipated New Drug Application submission to the U.S. Food and Drug Administration.

The company is developing buntanetap, an investigational once-daily oral therapy for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. Buntanetap works by inhibiting the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism of action. This approach targets underlying causes of neurodegeneration rather than just symptoms, representing a potentially significant advancement in treatment paradigms. The extended financial runway allows Annovis to continue advancing its ongoing clinical studies and regulatory preparations without immediate funding concerns.

The importance of this financing extends beyond mere corporate operations. For patients suffering from neurodegenerative diseases, this funding represents continued progress toward potentially disease-modifying treatments. Alzheimer's disease alone affects millions worldwide with limited treatment options, while Parkinson's disease progressively impairs motor function. The ability to fund operations through 2027 provides stability for the clinical development program, increasing the likelihood that buntanetap will complete necessary trials and reach regulatory review stages. This stability is particularly important given the high failure rate of neurological drug development and the substantial resources required for Phase 3 trials.

From an investment perspective, the successful offering demonstrates continued market confidence in Annovis Bio's approach despite broader biotech funding challenges. The company's focus on multiple neurodegenerative conditions through a single mechanism represents an efficient development strategy that could address significant unmet medical needs across several disease areas. The financing milestone comes at a critical juncture as the company prepares for important data readouts and regulatory submissions that will determine buntanetap's future development path and potential market approval.

More information about the company is available at https://www.annovisbio.com, and additional updates relating to ANVS are accessible through the company's newsroom at https://ibn.fm/ANVS. The press release announcing this financing was distributed through BioMedWire, a specialized communications platform focused on biotechnology and biomedical sciences that provides distribution services through its network, with more details available at https://www.BioMedWire.com.